TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05134870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mimic- game and groove- Telerehabilitation
Description: Participants will mimic the exergaming-based animation videos shown to them by the health coach. They will also wear a wearable device that will measure the heart rate and physical activity during the training. The intervention will have 12 sessions for 4 weeks, each session for 1.5 hours, including warm-ups and cool-down. Warm-up and cool down are for 20 minutes. Additionally, Participants are provided with a set of balance exercises which includes non-interactive balance games (stepping forward, backward, sideways), Tai-Chi, Weight shifting (to right leg, left leg and practice distributing equal weights on both the legs), Aerobic (stepping in place), dance, strength, and stretching
Study: NCT04009915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS
Description: Patients undergo a standard VATS operation for stage II-III lung cancer called a lobectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Patients undergo a standard open operation for stage II-III lung cancer called a lobectomy.
Study: NCT02742259

Intervention type: DEVICE
Intervention: Blood Draw
Description: Blood draws only - non-diagnostic, non-treatment

Intervention type: DEVICE
Intervention: Blood Draw
Description: Blood draws only - non-diagnostic, non-treatment
Study: NCT02882113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: same dose as Tacrolimus bid der day in 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: same dose as Tacrolimus bid der day in 24 weeks
Study: NCT00605644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOA-728
Description: Oral Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOA-728
Description: Oral Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOA-728
Description: Oral Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOA-728
Description: Oral Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02698969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm Ultrasonography
Description: Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diaphragm Ultrasonography
Description: Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurumuscual monitoring
Description: Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurumuscual monitoring
Description: Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium will be administered 0.6 mg\*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg\*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium will be administered 0.6 mg\*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg\*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanest will be administered 2 mcg\*kg-1 at the induction of general anesthesia and titrated 0.5 mcg\*kg-1 every 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanest will be administered 2 mcg\*kg-1 at the induction of general anesthesia and titrated 0.5 mcg\*kg-1 every 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered 2 mg\*kg-1 at the induction of general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered 2 mg\*kg-1 at the induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
Study: NCT01570036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeuVax vaccine
Description: At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
Study: NCT02842606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test meal
Description: The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
Study: NCT01690611

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Walking
Description: Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treadmill Walking
Description: Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: Real time feedback regarding body motion while walking.
Study: NCT03811353

Intervention type: DIAGNOSTIC_TEST
Intervention: T-MOE
Description: Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: T-MOE
Description: Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale.
Study: NCT01647269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral GPi Deep Brain Stimulation
Description: Bilateral GPi Deep Brain Stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral GPi Deep Brain Stimulation
Description: Bilateral GPi Deep Brain Stimulation
Study: NCT01676909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Well
Description: This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. There will be 3 booster sessions after the 12 sessions, once a month for 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Illness Education & Support Group
Description: The comparison condition will be a general Medical Illness Education and Support (MIES) group that will discuss common challenges experienced by those living with a wide range of chronic illnesses and behavioral and lifestyle management techniques that may help veterans to better handle chronic medical conditions that also meets for 12 weeks.
Study: NCT01498679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)
Description: ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered once daily in the evening via a NDPI
Study: NCT00226031

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Educational Material and Reminder
Description: Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Educational Material and Reminder
Description: Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
Study: NCT03587974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH-VIETNAM
Description: Family caregiver education, stress-reduction, and skill-training related to providing care for a person with Alzheimer's disease
Study: NCT02075268

Intervention type: DRUG
Group type: OTHER
Intervention: prasugrel
Description: prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
Study: NCT02866084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device
Description: The following parameters will be set for active treatments using the CVS Device:~* A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~* The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies.
Study: NCT03399487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378(Ceritinib)
Description: This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.
Study: NCT03063112

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency generator device
Description: sympathetic blockade or ablation of thoracic splanchnic nerves

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: sympathetic blockade or ablation of thoracic splanchnic nerves

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: C arm fluoroscopic device
Description: sympathetic blockade or ablation of thoracic splanchnic nerves

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethyl alcohol
Description: sympathetic blockade or ablation of thoracic splanchnic nerves
Study: NCT04115553

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: MRI examination
Description: Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. Standard MRI examination using a 32-channel head coil consists of angiographic, morphological and phase-contrast 2D flow sequences. The flow planes are set perpendicularly to the structure axis (blood or CSF regions). The velocity measured in the pixels inside the region of interest allow the calculation of a mean flow rate as well as the volume displaced during a cardiac cycle.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. Standard MRI examination using a 32-channel head coil consists of angiographic, morphological and phase-contrast 2D flow sequences. The flow planes are set perpendicularly to the structure axis (blood or CSF regions). The velocity measured in the pixels inside the region of interest allow the calculation of a mean flow rate as well as the volume displaced during a cardiac cycle.
Study: NCT03979287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interferential Current and Therapeutic Exercise Program
Description: The Interferential Current Program will be based on a bipolar application using the Sonopuls 692 device (Enraf Nonius, Rotterdam, The Netherlands). The current parameters will be: a) 4000Hz carrier frequency; and b) 60 Hz AMF with a modulation frequency of 90 Hz. The intensity of the current will be adapted to the sensitivity of each patient.~The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise Program
Description: The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises
Study: NCT01198977

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief telephone-based counseling
Description: Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education counseling
Description: Mailed informational video of exercise programs
Study: NCT04041635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimuli reduction
Description: Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
Study: NCT01600716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (Normal Saline)
Description: Placebo (normal saline) is administered into the detrusor at Day 1.
Study: NCT01940952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Donepezil 5mg or 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
Study: NCT02121535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T80/A5 mg FDC tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T80/A5 mg FDC tablet
Description: A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H12.5 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T80/A5/H12.5 ng FDC tablet
Description: A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H12.5 mf tablet
Description: A HCTZ 12.5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T80/A5/H12.5 mg FDC tablet
Study: NCT00698763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: from 0.125 mg to 2 mg in escalating doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical in appearance to active capsules
Study: NCT02353208

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Feeding of Bacon Bits
Description: Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will not be asked to chew bacon bits
Study: NCT02106598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescent cRGDY-PEG-Cy5.5-C dots
Study: NCT04029636

Intervention type: OTHER
Intervention: Inhaled Hyperpolarized Xenon-129
Description: How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant

Intervention type: OTHER
Intervention: Inhaled Hyperpolarized Xenon-129
Description: How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
Study: NCT02647619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiapex
Description: Injection of collagenase of primary dupytren cord

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle aponeurotomy
Description: 26 G needle multiple perforation tecqnique with local anesthetic
Study: NCT03997344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group nature hikes
Description: Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group urban hikes
Description: Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
Study: NCT04115553

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: ECG
Description: A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
Study: NCT02408276

Intervention type: OTHER
Intervention: dGEMERIC MRI technique
Description: Patients will be treated surgically (hip arthroscopy) or nonoperatively (physical therapy) and pain medications as needed. For surgical patients, cartilage samples and surgeon operative reports will be a source of research. For both cohorts, MRIs, radiographs and patient reported outcome surveys will be additional research sources.~All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant.